View Past PerformanceFluroTech バランスシートの健全性財務の健全性 基準チェック /16FluroTechの総株主資本はCA$-302.4K 、総負債はCA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれCA$128.7KとCA$431.1Kです。主要情報0%負債資本比率CA$0負債インタレスト・カバレッジ・レシオn/a現金CA$128.60kエクイティ-CA$302.38k負債合計CA$431.08k総資産CA$128.71k財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 03FluroTech Ltd. announced that it expects to receive CAD 22 million in fundingFluroTech Ltd. announced a best effort basis private placement of 5,500,000 subscription receipts at a price of CAD 4 per share for the gross proceeds of CAD 22,000,000 on May 1, 2024. The transaction is expected to be completed in Q2 2024.お知らせ • Mar 22FluroTech Ltd., Annual General Meeting, May 17, 2024FluroTech Ltd., Annual General Meeting, May 17, 2024.お知らせ • Mar 12FluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announced a private placement of minimum of 6,666,667 common shares at an issue price of CAD 0.075 per share for minimum gross proceeds of CAD 500,000.025 and maximum of 13,333,333 common shares at an issue price of CAD 0.075 per share for maximum gross proceeds of CAD 999,999.975 on March 11, 2024. The financing remains subject to TSXV approval.お知らせ • Dec 22+ 1 more updateFluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announces private placement of 5,000,000 shares at an issue price of CAD 0.10 per share for minimum gross proceeds of CAD 500,000 to 10,000,000 common shares at an issue price of CAD 0.10 per share for maximum gross proceeds of CAD 1,000,000 on December 21, 2023. The financing is subject to the approval of the TSXV stock exchange.お知らせ • Jan 14FluroTech Ltd., Annual General Meeting, Mar 20, 2023FluroTech Ltd., Annual General Meeting, Mar 20, 2023.お知らせ • Jan 04An unknown individual buyer acquired FluroTest Systems Ltd from FluroTech Ltd. for CAD 1.An unknown individual buyer acquired FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. for CAD 1 on December 31, 2022. An unknown individual buyer completed the acquisition of FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. on December 31, 2022.お知らせ • Apr 09FluroTech Ltd. Provides Operational Update and Announces Pause on Further Development of its Pandemic and Emerging Disease Defense PlatformFluroTech Ltd. announced that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require additional financing to complete the technology through to regulatory approvals in order to become commercial. To that end, management continues to pursue financing options. Readers are cautioned that, although the Company has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly the Company is not currently making any express or implied claims that its PEDDP can, or will be able to, accurately detect the COVID-19 virus.お知らせ • Dec 08FluroTech LTD. Provides System Development Update; Announces Further Progress Optimizing the Immunoassay for Sars-Cov-2 DetectionFluroTech LTD. and wholly owned subsidiary FluroTest Diagnostic Systems provided a progress update on its efforts to bring its Pandemic Response Platform to market. The Company believes that its technology will represent a disruptive breakthrough in the development of its high volume, high speed “point of entry/point of access” testing solution. Important breakthroughs include: Fewer steps in sample processing – The simplified sample processing protocol has eliminated 43% of the sample processing steps, thus reducing time and complexity. Testing protocol simplification – As a result of the simplification of the testing protocol, the Company has made great strides in refining the type of instrumentation required to read processed test samples, further reducing the time necessary for each reading as well as reducing the capital cost of field-based instrumentation hardware by as much as 50% as well as reducing the equipment footprint by 40%. Both of these improvements make the system accessible to many more “point of entry” environments, such as airports, schools, university campuses, hospital entrances, to name a few. Materials cost per test reduced – While initial estimates of the direct cost of each test to the Company would approximate USD 5.00 to USD 6.00, the Company’s optimized protocol development efforts are aimed at producing a direct cost per test of approximately $1.00, thus providing the Company with flexibility in pricing tests much lower to the consumer while still maintaining favorable gross profit margins. It is hoped that this costing will lend itself to mass testing at an affordable cost and in return should assist in helping to reduce super spreader events. Platform solution cost per test improved – The optimization of sample processing and equipment necessary to process tests will lower the capital cost per platform by as much as 50%, thus making the platform solution more affordable to more potential customers and enabling more frequent testing. The Company expects in 3 to 4 months it will complete test optimization, protocol development, and prepare to enter clinical trials. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.お知らせ • Jul 14FluroTech Announces Pre-Emergency Use Authorization Filing with U.S. Food and Drug AdministrationFluroTech LTD and FluroTest Diagnostic Systems, announced it has filed its Pre-Emergency Use Authorization Request with the U.S. Food and Drug Administration. The Pre-EUA submission is the company’s latest step taken as it seeks authorization of its FluroTest Pandemic Response Platform, designed to facilitate widespread point of access and surge-scale SARS-CoV-2 testing by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. Notable updates include: Pre-EUA Submission Delivery: Early engagement now progressing between FluroTest and the Agency to facilitate a speedy and fulsome final submission. These interactions help guide the FDA’s ability to review and potentially grant the EUA. As described by the FDA, “A Pre-EUA package contains data and information about the safety, quality, and efficacy of the product, its intended use under a future or current EUA, and information about the emergency or potential emergency situation. The pre-EUA process allows FDA scientific and technical subject matter experts to begin a review of information and assist in the development of conditions of authorization, fact sheets, and other documentation that would be needed for an EUA in advance of an emergency and also helps to facilitate complete EUA requests during a current emergency declaration.” Immunoassay Development: Positive results obtained on initial testing with the use of an inactivated virus. This is a critical step in immunoassay development. Final optimization of the buffer chemistry, to ensure optimal test performance with clinical samples from the field, is being performed. FluroTest immunoassay incorporates the same inactivation detergent that was also used in Gates Foundation funded immunoassays. Inactivation detergent is used in the sample collection device to make the saliva sample safe for transport, storage and handling. Manufacturing: Pre-production development of three functioning pandemic defense platform systems is now complete. Newly added Biological Safety Cabinets have been built, tested, and approved for use. Clinical Trial Update: Pending added guidance from the FDA on its pre-EUA submission, FluroTest will proceed with sample collections from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. Customer Data and Privacy Protection - protocol now established and in place to manage test taker’s required data (e.g., name and link to the saliva sample, interface with all automated equipment and fluorescence reader, test results management, etc.). FluroTest continues to work with clinical trials partner Toolbox Medical Innovations to fulfill additional requirements to support final submissions for Emergency Use Authorization from the U.S. Food and Drug Administration and Health Canada for an Interim Order Authorization. Toolbox has expertise in helping organizations surpass each step of the submission process from clinical study design and development, all the way up to regulatory planning and support, allowing them to provide a fast and efficient path to FDA and other approvals for diagnostic products. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.お知らせ • May 27FluroTech Ltd. (TSXV:TEST) acquired 26.3% stake in FluroTest Systems Ltd.FluroTech Ltd. (TSXV:TEST) acquired 26.3% stake in FluroTest Systems Ltd effective December 31, 2021.お知らせ • May 11FluroTech Ltd. and FluroTest Diagnostics Systems Provide Clinical Trial Update for High Volume COVID-19 Rapid Antigen Testing SystemFluroTech Ltd. and FluroTest Diagnostics Systems ('FluroTest' or The Company) announced the next phase of its ongoing clinical trials with its trial partner Toolbox Medical Innovations ('Toolbox'). The Company reported that approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals, are being identified from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. The data collected from this and the upcoming pilot program with California-based Total Testing Solutions will be used to support submissions for Emergency Use Authorization (‘EUA’) from the U.S. Food and Drug Administration (‘FDA’) and Health Canada for an Interim Order Authorization. Toolbox has expertise in helping organizations surpass each step of the submission process from clinical study design and development, all the way up to regulatory planning and support, allowing them to provide a fast and efficient path to FDA and other approvals for diagnostic products. The 600- patient trial will be one of the most extensive conducted to date for FDA /Health Canada submissions. FluroTest's high-volume antigen system is designed to facilitate very fast and accurate point of access testing of individuals by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. High-risk pandemic environments supported will include athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, manufacturing facilities, schools and colleges, hospitals and large healthcare facilities, transportation and distribution hubs and other large businesses.お知らせ • May 06Flurotest Prepares to Detect SARS-CoV-2 Variants of Concern with High- Throughput COVID-19 Testing PlatformFluroTech Ltd. announced based on the data collected to date that the FluroTest platform will be capable of detecting the primary variants of concern now spreading across North America and fueling serious outbreaks around the world. Many of the variants of concern are mutations that alter the viral structure through the spike (‘S’) protein found on the molecular surface. FluroTest's antigen immunoassay detects the nucleocapsid (‘N’) protein, which is found deep within the virus' structure and, so far, remains relatively unaffected by major mutations in the main variants of concern. FluroTest works with the world's leading reagent suppliers of the antibody pairs that are used in the Pandemic Defense Platform Immunoassay. Additionally, they have confirmed that the antibody pairs FluroTest uses can detect the UK, South African and Brazilian variants and they continually collect data on emerging variants of concern. Variants of the SARS-CoV-2 virus first identified in the UK, South Africa, and Brazil appear to be more transmissible than the original wild viral strain first identified in 2019. The increased frequency and spread of these variants of concern has solidified the importance of widespread screening and surveillance, two of many uses for the FluroTest Pandemic Defense Platform. Leaders from FluroTest's target industries have openly stated that vaccine passports alone will not be sufficient. Accurate and verifiable testing is also extremely important to reopening the economy. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.お知らせ • Mar 05Flurotech Ltd. to Carry Out Clinical Trials of the Flurotest Pandemic Response PlatformFluroTech Ltd. together with joint venture FluroTest, LLC announce that an agreement with Toolbox Medical Innovations (“Toolbox”) has been signed this week to carry out clinical trials of the FluroTest pandemic response platform alongside a comparator RT-PCR assay for performance detection of SARS-CoV-2 in saliva samples.お知らせ • Mar 03FluroTech Ltd. Appoints Phil Farrelly to its Advisory BoardFluroTech Ltd. announced that visionary inventor and Hudson Robotics Founder and President Phil Farrelly has joined FluroTech’s advisory board. Mr. Farrelly is a noted life sciences and lab automation authority and innovator. He founded Hudson Robotics in 1983, establishing the company as a market leader in microplate automation, laboratory robotics, liquid handling and customized software-driven laboratory automation solutions for life sciences research. The company develops specialized tools used in areas such as drug discovery, clinical research and pharmaceutical development, including high throughput screening, proteomics and genomics.お知らせ • Feb 20FluroTech and Hudson Robotics Begin Pandemic Response Unit Pre-ProductionFluroTech Ltd. together with joint venture FluroTest, LLC announced that pre-production development of three functioning pandemic defense platform systems are now underway with laboratory robotics automation partner, Hudson Robotics. These units will be used to pilot automated testing protocols that facilitate point-of-service, rapid testing of individuals with high-speed, high throughput functionality, providing COVID-19 testing results within minutes instead of days. The systems are designed to be portable, and will be deployed for controlled clinical, customer, and field trials over the coming months. The data collected will be used to support FluroTest's submission for Emergency Use Authorization from the U.S. Food and Drug Administration and Health Canada for an Interim Order Authorization. Future submissions to additional regulatory bodies around the globe are also being considered. The Company will provide additional updates to the market as appropriate.お知らせ • Feb 18Flurotech Adds Life Sciences Expert Dr. Timothy J. Holzer to Scientific Advisory BoardFluroTech Ltd. announced that accomplished scientist and diagnostic test commercialization expert Dr. Timothy Holzer has joined FluroTech’s advisory board. Dr. Holzer is helping to design, manage and oversee the Company efforts as it embarks on its large-scale clinical trial with a major U.S.-based healthcare system partner to validate the performance of the FluroTest Pandemic Defense System.お知らせ • Feb 05Flurotech Ltd. Announces Management ChangesFluroTech Ltd. announced that Brian Shield has joined FluroTech’s advisory board. Mr. Shield will help guide the company’s business and innovation strategy, supporting FluroTest’s market access efforts and the planned rollout of its pandemic defense system across sports and entertainment industries, pending emergency use authorization (EUA) with the FDA. In his current role, Mr. Shield is responsible for technology for the Boston Red Sox and Fenway Sports Management, leading the technology team on all phases of the Red Sox IT strategy and implementation. Mr. Shield co-founded BostonCIO and is the national chair of InspireCIO, the preeminent executive peer leadership network of Chief Information Officers (CIOs) across North America. He also serves as an advisor to Bindle Systems (software platform for COVID-19 health status), ISTA (International Sports & Technology Association), SEAT (Sports & Entertainment Alliance in Technology), and OvalEdge (data catalogue and governance platform). Prior to the Red Sox, Mr. Shield served as EVP and CIO of The Weather Channel where for 14 years he oversaw all technology, including weather.com, mobility, data systems and analytics, broadcast television and IT. Before this, he served as SVP and CIO of online delivery pioneer FTD.お知らせ • Jan 22FluroTech Ltd. announced that it has received CAD 2.531254 million in fundingOn January 21, 2021, FluroTech Ltd. (TSXV:TEST) closed the transaction. The company issued 18,750,026 units for gross proceeds of $2,531,253 in the transaction. The company issued 15,644,844 units for gross proceeds of $2,112,054 in the second and final tranche of the transaction. The company has paid CAD 59,745.34 and issued an aggregate of 442,557 finders options as finders fees in connection with the closing of the second tranche of the transaction. Each Finder’s Option entitles the holder thereof to acquire one Common Share at a price of CAD 0.15 per share for a period of 12 months from the date such Finder’s Option was issued. The securities issued in the transaction are subject to hold period until May 22, 2021.お知らせ • Dec 04Flurotech Ltd. to Launch Its First Product Solution to Provide UniversitiesFluroTech Ltd. will launch its first product solution to provide universities, colleges, as well as primary and secondary schools and their communities with a high frequency testing solution enabling them to open safely. The FluroTest schools testing solution is a COVID testing platform that the Company anticipates will be capable of running 3,000 tests per hour directly at the point of collection with results immediately available to every test taker within 5 minutes. This enables schools to test all students, faculty, and administrators daily if they choose to do so. The Company has partnered with a number of mobile laboratory providers to provide schools with maximum flexibility in where they might locate the Platform in their campus environments. By combining and leveraging the well-developed disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing, FluroTest's patent pending pandemic defense platform (the "Platform") is designed to achieve throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes. FluroTest believes its Platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.お知らせ • Nov 20Flurotech Ltd. Announces Its Safe Air Travel Product SolutionFluroTech Ltd. launch its first product solution aimed at solving the testing problems airlines and airport terminal operators face as they work to make air travel safe for domestic and international travel. The FluroTest air travel solution is a COVID testing platform that the Company anticipates will be capable of running 3,000 tests per hour directly at the point of collection with accurate results immediately available to every passenger within 5 minutes. Systems will be placed in airport terminal locations enabling passengers to rapidly test and confirm their viral status before they reach the ticket counter to check their bags, or before they proceed to the normal airport security process. Platforms can be configured to assure high traffic areas have plenty of testing capacity to manage peak passenger demand.お知らせ • Nov 19Flurotech Ltd. Announces Stadium and Arena Product SolutionFluroTech Ltd. announced that it will launch its first product solution aimed at solving the testing problems facing the operators of large stadiums, arenas, and other high capacity venues. The FluroTest stadium and arena product solution is a COVID testing platform capable of running 3,000 tests per hour directly at the point of collection with results immediately available to every test taker within 5 minutes. This enables the safe opening of stadiums, arenas, airports, and other high traffic environments. Platforms can be configured to open any 60,000-seat indoor arena or outdoor stadium to full capacity in less than 2 hours. By combining and leveraging the well-developed disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing, FluroTest's patent pending pandemic defense platform is designed to achieve throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes. FluroTest believes its Platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to: colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.お知らせ • Nov 13FluroTech Ltd. Announces Joint Venture SARS-CoV2 Test Method OptimizationFluroTech Ltd. announced that has begun optimization of its SARS-CoV2 rapid detection test method with nanoComposix. The purpose of optimization is to advance FluroTest’s test method from proof of concept to commercial scale production readiness as it prepares for the U.S. Food and Drug Administration’s review process. By combining and leveraging the disciplines of robotics automation, biochemistry (antibody labeling and binding), fluorescence detection and cloud computing, FluroTest believes it is creating the first pandemic defense platform (the “Platform”) of its kind, achieving throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes.お知らせ • Nov 06FluroTech Ltd. announced that it expects to receive CAD 4 million in funding from Alumina Partners (Ontario) Ltd.FluroTech Ltd. (TSXV:TEST) announced that it has entered into an investment agreement for an equity draw down facility for the gross proceeds of CAD 4 million on November 5, 2020. The transaction will include participation from new investor Alumina Partners (Ontario) Ltd.. The company can draw down up to $250,000 in multiple tranches. The company will issue units in the transaction. Each unit consisting of one common share and one common share purchase warrant at discounts ranging from 15% to 25% of the closing price of the common shares on the TSX Venture Exchange on the day prior to the company’s drawdown notice to investor. Each tranche shall occur at the option of the company, through the 24-month term of the agreement. The exercise price of the warrants will be at a 25% premium over market price of the shares, and will have a term of 60 months. Each tranche will be subject to TSX Venture Exchange approval. All securities will be subject to a statutory hold period that expires four months and one day from issuance.財務状況分析短期負債: FLRL.Fは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。長期負債: FLRL.Fは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。デット・ツー・エクイティの歴史と分析負債レベル: FLRL.Fは負債がありません。負債の削減: FLRL.Fの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: FLRL.Fは、現在の フリーキャッシュフロー に基づくと、キャッシュランウェイ が 1 年未満です。キャッシュランウェイの予測: フリーキャッシュフローが毎年40.4 % の歴史的率で成長し続ける場合、 FLRL.Fのキャッシュランウェイは 1 年未満になります。健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 15:32終値2026/04/28 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FluroTech Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 03FluroTech Ltd. announced that it expects to receive CAD 22 million in fundingFluroTech Ltd. announced a best effort basis private placement of 5,500,000 subscription receipts at a price of CAD 4 per share for the gross proceeds of CAD 22,000,000 on May 1, 2024. The transaction is expected to be completed in Q2 2024.
お知らせ • Mar 22FluroTech Ltd., Annual General Meeting, May 17, 2024FluroTech Ltd., Annual General Meeting, May 17, 2024.
お知らせ • Mar 12FluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announced a private placement of minimum of 6,666,667 common shares at an issue price of CAD 0.075 per share for minimum gross proceeds of CAD 500,000.025 and maximum of 13,333,333 common shares at an issue price of CAD 0.075 per share for maximum gross proceeds of CAD 999,999.975 on March 11, 2024. The financing remains subject to TSXV approval.
お知らせ • Dec 22+ 1 more updateFluroTech Ltd. announced that it expects to receive CAD 1 million in fundingFluroTech Ltd. announces private placement of 5,000,000 shares at an issue price of CAD 0.10 per share for minimum gross proceeds of CAD 500,000 to 10,000,000 common shares at an issue price of CAD 0.10 per share for maximum gross proceeds of CAD 1,000,000 on December 21, 2023. The financing is subject to the approval of the TSXV stock exchange.
お知らせ • Jan 14FluroTech Ltd., Annual General Meeting, Mar 20, 2023FluroTech Ltd., Annual General Meeting, Mar 20, 2023.
お知らせ • Jan 04An unknown individual buyer acquired FluroTest Systems Ltd from FluroTech Ltd. for CAD 1.An unknown individual buyer acquired FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. for CAD 1 on December 31, 2022. An unknown individual buyer completed the acquisition of FluroTest Diagnostic Systems Ltd. from FluroTech Ltd. on December 31, 2022.
お知らせ • Apr 09FluroTech Ltd. Provides Operational Update and Announces Pause on Further Development of its Pandemic and Emerging Disease Defense PlatformFluroTech Ltd. announced that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require additional financing to complete the technology through to regulatory approvals in order to become commercial. To that end, management continues to pursue financing options. Readers are cautioned that, although the Company has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly the Company is not currently making any express or implied claims that its PEDDP can, or will be able to, accurately detect the COVID-19 virus.
お知らせ • Dec 08FluroTech LTD. Provides System Development Update; Announces Further Progress Optimizing the Immunoassay for Sars-Cov-2 DetectionFluroTech LTD. and wholly owned subsidiary FluroTest Diagnostic Systems provided a progress update on its efforts to bring its Pandemic Response Platform to market. The Company believes that its technology will represent a disruptive breakthrough in the development of its high volume, high speed “point of entry/point of access” testing solution. Important breakthroughs include: Fewer steps in sample processing – The simplified sample processing protocol has eliminated 43% of the sample processing steps, thus reducing time and complexity. Testing protocol simplification – As a result of the simplification of the testing protocol, the Company has made great strides in refining the type of instrumentation required to read processed test samples, further reducing the time necessary for each reading as well as reducing the capital cost of field-based instrumentation hardware by as much as 50% as well as reducing the equipment footprint by 40%. Both of these improvements make the system accessible to many more “point of entry” environments, such as airports, schools, university campuses, hospital entrances, to name a few. Materials cost per test reduced – While initial estimates of the direct cost of each test to the Company would approximate USD 5.00 to USD 6.00, the Company’s optimized protocol development efforts are aimed at producing a direct cost per test of approximately $1.00, thus providing the Company with flexibility in pricing tests much lower to the consumer while still maintaining favorable gross profit margins. It is hoped that this costing will lend itself to mass testing at an affordable cost and in return should assist in helping to reduce super spreader events. Platform solution cost per test improved – The optimization of sample processing and equipment necessary to process tests will lower the capital cost per platform by as much as 50%, thus making the platform solution more affordable to more potential customers and enabling more frequent testing. The Company expects in 3 to 4 months it will complete test optimization, protocol development, and prepare to enter clinical trials. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.
お知らせ • Jul 14FluroTech Announces Pre-Emergency Use Authorization Filing with U.S. Food and Drug AdministrationFluroTech LTD and FluroTest Diagnostic Systems, announced it has filed its Pre-Emergency Use Authorization Request with the U.S. Food and Drug Administration. The Pre-EUA submission is the company’s latest step taken as it seeks authorization of its FluroTest Pandemic Response Platform, designed to facilitate widespread point of access and surge-scale SARS-CoV-2 testing by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. Notable updates include: Pre-EUA Submission Delivery: Early engagement now progressing between FluroTest and the Agency to facilitate a speedy and fulsome final submission. These interactions help guide the FDA’s ability to review and potentially grant the EUA. As described by the FDA, “A Pre-EUA package contains data and information about the safety, quality, and efficacy of the product, its intended use under a future or current EUA, and information about the emergency or potential emergency situation. The pre-EUA process allows FDA scientific and technical subject matter experts to begin a review of information and assist in the development of conditions of authorization, fact sheets, and other documentation that would be needed for an EUA in advance of an emergency and also helps to facilitate complete EUA requests during a current emergency declaration.” Immunoassay Development: Positive results obtained on initial testing with the use of an inactivated virus. This is a critical step in immunoassay development. Final optimization of the buffer chemistry, to ensure optimal test performance with clinical samples from the field, is being performed. FluroTest immunoassay incorporates the same inactivation detergent that was also used in Gates Foundation funded immunoassays. Inactivation detergent is used in the sample collection device to make the saliva sample safe for transport, storage and handling. Manufacturing: Pre-production development of three functioning pandemic defense platform systems is now complete. Newly added Biological Safety Cabinets have been built, tested, and approved for use. Clinical Trial Update: Pending added guidance from the FDA on its pre-EUA submission, FluroTest will proceed with sample collections from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. Customer Data and Privacy Protection - protocol now established and in place to manage test taker’s required data (e.g., name and link to the saliva sample, interface with all automated equipment and fluorescence reader, test results management, etc.). FluroTest continues to work with clinical trials partner Toolbox Medical Innovations to fulfill additional requirements to support final submissions for Emergency Use Authorization from the U.S. Food and Drug Administration and Health Canada for an Interim Order Authorization. Toolbox has expertise in helping organizations surpass each step of the submission process from clinical study design and development, all the way up to regulatory planning and support, allowing them to provide a fast and efficient path to FDA and other approvals for diagnostic products. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.
お知らせ • May 27FluroTech Ltd. (TSXV:TEST) acquired 26.3% stake in FluroTest Systems Ltd.FluroTech Ltd. (TSXV:TEST) acquired 26.3% stake in FluroTest Systems Ltd effective December 31, 2021.
お知らせ • May 11FluroTech Ltd. and FluroTest Diagnostics Systems Provide Clinical Trial Update for High Volume COVID-19 Rapid Antigen Testing SystemFluroTech Ltd. and FluroTest Diagnostics Systems ('FluroTest' or The Company) announced the next phase of its ongoing clinical trials with its trial partner Toolbox Medical Innovations ('Toolbox'). The Company reported that approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals, are being identified from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. The data collected from this and the upcoming pilot program with California-based Total Testing Solutions will be used to support submissions for Emergency Use Authorization (‘EUA’) from the U.S. Food and Drug Administration (‘FDA’) and Health Canada for an Interim Order Authorization. Toolbox has expertise in helping organizations surpass each step of the submission process from clinical study design and development, all the way up to regulatory planning and support, allowing them to provide a fast and efficient path to FDA and other approvals for diagnostic products. The 600- patient trial will be one of the most extensive conducted to date for FDA /Health Canada submissions. FluroTest's high-volume antigen system is designed to facilitate very fast and accurate point of access testing of individuals by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. High-risk pandemic environments supported will include athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, manufacturing facilities, schools and colleges, hospitals and large healthcare facilities, transportation and distribution hubs and other large businesses.
お知らせ • May 06Flurotest Prepares to Detect SARS-CoV-2 Variants of Concern with High- Throughput COVID-19 Testing PlatformFluroTech Ltd. announced based on the data collected to date that the FluroTest platform will be capable of detecting the primary variants of concern now spreading across North America and fueling serious outbreaks around the world. Many of the variants of concern are mutations that alter the viral structure through the spike (‘S’) protein found on the molecular surface. FluroTest's antigen immunoassay detects the nucleocapsid (‘N’) protein, which is found deep within the virus' structure and, so far, remains relatively unaffected by major mutations in the main variants of concern. FluroTest works with the world's leading reagent suppliers of the antibody pairs that are used in the Pandemic Defense Platform Immunoassay. Additionally, they have confirmed that the antibody pairs FluroTest uses can detect the UK, South African and Brazilian variants and they continually collect data on emerging variants of concern. Variants of the SARS-CoV-2 virus first identified in the UK, South Africa, and Brazil appear to be more transmissible than the original wild viral strain first identified in 2019. The increased frequency and spread of these variants of concern has solidified the importance of widespread screening and surveillance, two of many uses for the FluroTest Pandemic Defense Platform. Leaders from FluroTest's target industries have openly stated that vaccine passports alone will not be sufficient. Accurate and verifiable testing is also extremely important to reopening the economy. Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.
お知らせ • Mar 05Flurotech Ltd. to Carry Out Clinical Trials of the Flurotest Pandemic Response PlatformFluroTech Ltd. together with joint venture FluroTest, LLC announce that an agreement with Toolbox Medical Innovations (“Toolbox”) has been signed this week to carry out clinical trials of the FluroTest pandemic response platform alongside a comparator RT-PCR assay for performance detection of SARS-CoV-2 in saliva samples.
お知らせ • Mar 03FluroTech Ltd. Appoints Phil Farrelly to its Advisory BoardFluroTech Ltd. announced that visionary inventor and Hudson Robotics Founder and President Phil Farrelly has joined FluroTech’s advisory board. Mr. Farrelly is a noted life sciences and lab automation authority and innovator. He founded Hudson Robotics in 1983, establishing the company as a market leader in microplate automation, laboratory robotics, liquid handling and customized software-driven laboratory automation solutions for life sciences research. The company develops specialized tools used in areas such as drug discovery, clinical research and pharmaceutical development, including high throughput screening, proteomics and genomics.
お知らせ • Feb 20FluroTech and Hudson Robotics Begin Pandemic Response Unit Pre-ProductionFluroTech Ltd. together with joint venture FluroTest, LLC announced that pre-production development of three functioning pandemic defense platform systems are now underway with laboratory robotics automation partner, Hudson Robotics. These units will be used to pilot automated testing protocols that facilitate point-of-service, rapid testing of individuals with high-speed, high throughput functionality, providing COVID-19 testing results within minutes instead of days. The systems are designed to be portable, and will be deployed for controlled clinical, customer, and field trials over the coming months. The data collected will be used to support FluroTest's submission for Emergency Use Authorization from the U.S. Food and Drug Administration and Health Canada for an Interim Order Authorization. Future submissions to additional regulatory bodies around the globe are also being considered. The Company will provide additional updates to the market as appropriate.
お知らせ • Feb 18Flurotech Adds Life Sciences Expert Dr. Timothy J. Holzer to Scientific Advisory BoardFluroTech Ltd. announced that accomplished scientist and diagnostic test commercialization expert Dr. Timothy Holzer has joined FluroTech’s advisory board. Dr. Holzer is helping to design, manage and oversee the Company efforts as it embarks on its large-scale clinical trial with a major U.S.-based healthcare system partner to validate the performance of the FluroTest Pandemic Defense System.
お知らせ • Feb 05Flurotech Ltd. Announces Management ChangesFluroTech Ltd. announced that Brian Shield has joined FluroTech’s advisory board. Mr. Shield will help guide the company’s business and innovation strategy, supporting FluroTest’s market access efforts and the planned rollout of its pandemic defense system across sports and entertainment industries, pending emergency use authorization (EUA) with the FDA. In his current role, Mr. Shield is responsible for technology for the Boston Red Sox and Fenway Sports Management, leading the technology team on all phases of the Red Sox IT strategy and implementation. Mr. Shield co-founded BostonCIO and is the national chair of InspireCIO, the preeminent executive peer leadership network of Chief Information Officers (CIOs) across North America. He also serves as an advisor to Bindle Systems (software platform for COVID-19 health status), ISTA (International Sports & Technology Association), SEAT (Sports & Entertainment Alliance in Technology), and OvalEdge (data catalogue and governance platform). Prior to the Red Sox, Mr. Shield served as EVP and CIO of The Weather Channel where for 14 years he oversaw all technology, including weather.com, mobility, data systems and analytics, broadcast television and IT. Before this, he served as SVP and CIO of online delivery pioneer FTD.
お知らせ • Jan 22FluroTech Ltd. announced that it has received CAD 2.531254 million in fundingOn January 21, 2021, FluroTech Ltd. (TSXV:TEST) closed the transaction. The company issued 18,750,026 units for gross proceeds of $2,531,253 in the transaction. The company issued 15,644,844 units for gross proceeds of $2,112,054 in the second and final tranche of the transaction. The company has paid CAD 59,745.34 and issued an aggregate of 442,557 finders options as finders fees in connection with the closing of the second tranche of the transaction. Each Finder’s Option entitles the holder thereof to acquire one Common Share at a price of CAD 0.15 per share for a period of 12 months from the date such Finder’s Option was issued. The securities issued in the transaction are subject to hold period until May 22, 2021.
お知らせ • Dec 04Flurotech Ltd. to Launch Its First Product Solution to Provide UniversitiesFluroTech Ltd. will launch its first product solution to provide universities, colleges, as well as primary and secondary schools and their communities with a high frequency testing solution enabling them to open safely. The FluroTest schools testing solution is a COVID testing platform that the Company anticipates will be capable of running 3,000 tests per hour directly at the point of collection with results immediately available to every test taker within 5 minutes. This enables schools to test all students, faculty, and administrators daily if they choose to do so. The Company has partnered with a number of mobile laboratory providers to provide schools with maximum flexibility in where they might locate the Platform in their campus environments. By combining and leveraging the well-developed disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing, FluroTest's patent pending pandemic defense platform (the "Platform") is designed to achieve throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes. FluroTest believes its Platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.
お知らせ • Nov 20Flurotech Ltd. Announces Its Safe Air Travel Product SolutionFluroTech Ltd. launch its first product solution aimed at solving the testing problems airlines and airport terminal operators face as they work to make air travel safe for domestic and international travel. The FluroTest air travel solution is a COVID testing platform that the Company anticipates will be capable of running 3,000 tests per hour directly at the point of collection with accurate results immediately available to every passenger within 5 minutes. Systems will be placed in airport terminal locations enabling passengers to rapidly test and confirm their viral status before they reach the ticket counter to check their bags, or before they proceed to the normal airport security process. Platforms can be configured to assure high traffic areas have plenty of testing capacity to manage peak passenger demand.
お知らせ • Nov 19Flurotech Ltd. Announces Stadium and Arena Product SolutionFluroTech Ltd. announced that it will launch its first product solution aimed at solving the testing problems facing the operators of large stadiums, arenas, and other high capacity venues. The FluroTest stadium and arena product solution is a COVID testing platform capable of running 3,000 tests per hour directly at the point of collection with results immediately available to every test taker within 5 minutes. This enables the safe opening of stadiums, arenas, airports, and other high traffic environments. Platforms can be configured to open any 60,000-seat indoor arena or outdoor stadium to full capacity in less than 2 hours. By combining and leveraging the well-developed disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing, FluroTest's patent pending pandemic defense platform is designed to achieve throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes. FluroTest believes its Platform can benefit organizations serving large, concentrated populations and bearing significant pandemic risk, forcing them to incur consequential business disruptions and closures. Examples include, but are not limited to: colleges and universities, hospitals & large healthcare complexes, athletic stadiums & large performance venues, corporate campus environments, large office buildings & complexes, shopping malls and centers, retail working warehouses, factories, food processing plants, airlines, as well as any public transportation hub such as subway entrances and airport terminals.
お知らせ • Nov 13FluroTech Ltd. Announces Joint Venture SARS-CoV2 Test Method OptimizationFluroTech Ltd. announced that has begun optimization of its SARS-CoV2 rapid detection test method with nanoComposix. The purpose of optimization is to advance FluroTest’s test method from proof of concept to commercial scale production readiness as it prepares for the U.S. Food and Drug Administration’s review process. By combining and leveraging the disciplines of robotics automation, biochemistry (antibody labeling and binding), fluorescence detection and cloud computing, FluroTest believes it is creating the first pandemic defense platform (the “Platform”) of its kind, achieving throughput rates of 3,000 tests per hour with results on the mobile device of the test taker in 5 minutes.
お知らせ • Nov 06FluroTech Ltd. announced that it expects to receive CAD 4 million in funding from Alumina Partners (Ontario) Ltd.FluroTech Ltd. (TSXV:TEST) announced that it has entered into an investment agreement for an equity draw down facility for the gross proceeds of CAD 4 million on November 5, 2020. The transaction will include participation from new investor Alumina Partners (Ontario) Ltd.. The company can draw down up to $250,000 in multiple tranches. The company will issue units in the transaction. Each unit consisting of one common share and one common share purchase warrant at discounts ranging from 15% to 25% of the closing price of the common shares on the TSX Venture Exchange on the day prior to the company’s drawdown notice to investor. Each tranche shall occur at the option of the company, through the 24-month term of the agreement. The exercise price of the warrants will be at a 25% premium over market price of the shares, and will have a term of 60 months. Each tranche will be subject to TSX Venture Exchange approval. All securities will be subject to a statutory hold period that expires four months and one day from issuance.